Cleerly ISCHEMIA vs HeartFlow Analysis

Both tools offer web-based or cloud-based platforms for analysis and reporting, suggesting good accessibility. Cleerly highlights 'comprehensive interactive web-based reports' and 'integration with PowerScribe via API' for streamlined workflow. HeartFlow emphasizes 'seamless clinical integration via upgraded workflow' and 'Roadmapu2122 Analysis' for efficient CCTA reading, along with quick patient results. Given both focus on intuitive interfaces and workflow integration, neither has a clear advantage in overall usability without direct user feedback.

Both are FDA-cleared and provide non-invasive assessment of CAD. Cleerly demonstrates high diagnostic accuracy and prognostic utility in trials like CREDENCE and PACIFIC, offering a '3-in-1 approach' for atherosclerosis, stenosis, and ischemia. HeartFlow boasts an extensive body of over '600 peer-reviewed publications', high accuracy against invasive FFR and IVUS, and has demonstrated a reduction in the need for invasive procedures and overall cost of care. HeartFlow's broader and longer-standing clinical evidence base and proven impact on patient pathways give it a slight edge.

While both require contacting for pricing, HeartFlow provides significantly more transparency regarding reimbursement. It operates on a 'fee-for-service model' and is 'covered by Medicare and most U.S. commercial payers,' with established Category I CPT codes for FFRct Analysis (75580) and AI-Enabled Quantitative Plaque Analysis (75577 for 2026), and established CMS payment rates. This clear reimbursement pathway and broad coverage reduce financial uncertainty for providers, offering a stronger value proposition.

Both tools are FDA-cleared, HIPAA compliant, and provide BAAs, indicating foundational readiness. However, HeartFlow explicitly states adherence to a broader range of international security and quality standards, including 'HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001'. Furthermore, HeartFlow has been adopted by 'more than 1,400 institutions' globally, including '80% of the top 50 heart hospitals in the U.S.', demonstrating a more extensive track record of enterprise-level deployment and trust.

Both are highly innovative in applying AI to non-invasive CAD diagnosis. HeartFlow's pioneering use of 'Computational Fluid Dynamics (CFD) for blood flow simulation' to derive FFRct represents a foundational and sophisticated technological innovation in the field. HeartFlow also leverages a 'proprietary data pipeline built from more than 160 million annotated CTA images'. While Cleerly offers a 'first-of-its-kind' approach with '37 measures of heart health' and a '3-in-1 approach', HeartFlow's deep integration of CFD for physiological assessment provides a distinct innovative edge.

HeartFlow provides a more detailed and comprehensive array of support services, including 'hands-on training,' 'expert coding support,' 'peer mentorship,' 'technology integration,' and 'case support'. This indicates a robust and multi-faceted support system designed for successful implementation and ongoing use within an enterprise setting. Cleerly also commits to customer success and provides resources like billing guidelines and patient education, but HeartFlow's listed services are more specific and extensive for enterprise clients.